MetaVia Inc.
MTVA
Rank in Stocks
#33008
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Share Price
$1.23
Last synced: 2026-10-19
Market Cap
$8.10M
Change (1 day)
-2.38%
Change (1 year)
-24.54%
Country
US
Trade MetaVia Inc. (MTVA)
Category
Healthcare
Number of shares outstanding for MetaVia Inc. (MTVA)
Number of shares outstanding as of June 2026: 5.93B
According to MetaVia Inc. latest financial reports and stock price the company's current number of shares outstanding is 5.93B. At the end of December 2023 the company had 5.07M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for MetaVia Inc. (MTVA) from 2014 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 5.93B | 7,547.03% |
| 2024 | 77.57M | 1,430.30% |
| 2023 | 5.07M | 1,475.68% |
| 2022 | 321.70K | 233.61% |
| 2021 | 96.43K | 42.71% |
| 2020 | 67.57K | 221.77% |
| 2019 | 21.00K | 18.56% |
| 2018 | 17.71K | 28.37% |
| 2017 | 13.80K | 78.15% |
| 2016 | 7.75K | 9.58% |
| 2015 | 7.07K | 0.00% |
| 2014 | 7.07K | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | -95.72% |
US
|
|
| 396.00M | -93.32% |
US
|
|
| 478.91M | -91.93% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -98.95% |
NL
|
